Drug Profile
Cytosine deaminase gene therapy
Alternative Names: AdCMV.CDLatest Information Update: 02 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline; Nonindustrial source
- Developer GSK; Nonindustrial source
- Class Antineoplastics; Cytosine deaminase flucytosine gene therapies; Pyrimidinones; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Coronary artery restenosis; Solid tumours
Most Recent Events
- 21 Jan 2006 Discontinued - Preclinical for Breast cancer in USA (unspecified route)
- 21 Jan 2006 Discontinued - Preclinical for Coronary artery restenosis in USA (unspecified route)
- 21 Jan 2006 Discontinued - Preclinical for Solid tumours in USA (unspecified route)